Research programme: synthetic natriuretic peptide - Capricor Therapeutics

Drug Profile

Research programme: synthetic natriuretic peptide - Capricor Therapeutics

Alternative Names: CU-NP

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Capricor Therapeutics
  • Class Natriuretic peptides
  • Mechanism of Action Natriuretic peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cardiovascular disorders; Kidney disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Kidney-disorders in USA (Parenteral)
  • 16 Feb 2017 Capricor Therapeutics has elected to terminate its license agreement with the Mayo Clinic for natriuretic peptide receptor agonists, including Cenderitide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top